Clinical Characterization of Patients with Chronic Spontaneous Urticaria according to Anti-TPO IgE Levels

  • Jorge Sánchez
    Group of Experimental and Clinical Allergy, Foundation “IPS Universitaria”, University of Antioquia, Medellín, Colombia
  • Andres Sánchez
    Group of Experimental and Clinical Allergy, Foundation “IPS Universitaria”, University of Antioquia, Medellín, Colombia
  • Ricardo Cardona
    Group of Experimental and Clinical Allergy, Foundation “IPS Universitaria”, University of Antioquia, Medellín, Colombia

説明

<jats:p><jats:italic>Background</jats:italic>. Chronic spontaneous urticaria (CSU) is a heterogeneous disease with some frequent comorbidities like autoimmune diseases, drug reactions, and inducible urticaria. IgE antibodies against thyroid peroxidase (anti-TPO IgE) could be associated with some of these clinical characteristics. <jats:italic>Objective</jats:italic>. To explore the clinical characteristics of CSU patients, according to the presence of anti-TPO IgE in serum. <jats:italic>Methods</jats:italic>. Anti-TPO IgE levels were measured during the clinical control period (Urticaria Activity Score, 0 point) and exacerbation period (≥3 points) in 100 CSU patients. Patients with self-reported exacerbation of skin involvement by foods, nonsteroidal anti-inflammatory drugs (NSAIDs), and physical triggers underwent controlled challenge tests. <jats:italic>Results</jats:italic>. We identified 2 groups of patients: (1) patients with anti-TPO IgE during the clinical control period or during an exacerbation, who had a higher frequency of atopy, asthma, and positive challenge test results with NSAIDs and (2) patients without anti-TPO IgE during any period, who had a higher frequency of positive challenge test results for inducible urticaria. Among the first group (anti-TPO IgE at any point), we identified 3 subgroups: patients with anti-TPO IgE during the clinical control period (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>12</mml:mn></mml:math>); patients with anti-TPO IgE during the clinical control period and significantly increased levels during an urticaria exacerbation (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>18</mml:mn></mml:math>); and patients with anti-TPO IgE only during an exacerbation (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>13</mml:mn></mml:math>). None of the patients with self-reported food reactions had a positive challenge test result. <jats:italic>Conclusion</jats:italic>. Anti-TPO IgE is a useful biomarker for differentiating between clinical phenotypes of patients with CSU. Elevation of anti-TPO IgE during exacerbation periods supports an association between this autoantibody and the pathogenesis of urticaria.</jats:p>

収録刊行物

被引用文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ